NCT04830943View on ClinicalTrials.gov

Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia

PHASE3CompletedINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

October 30, 2022

Conditions

Covid19 Related Anosmia and Aguesia

Interventions

DRUG

Cerebrolysin

Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks

Trial Locations (1)

71516

Assiut University Hospitals, Faculty of Medicine, Asyut

All Listed Sponsors

lead

Assiut University

OTHER

NCT04830943 - Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia | Biotech Hunter | Biotech Hunter